Home / Health / Obesity Jabs Trial Begins in Manchester
Obesity Jabs Trial Begins in Manchester
8 Dec, 2025
Summary
- A five-year trial assessing weight loss jab impact has started.
- Up to 3,000 people will participate in this real-world study.
- The trial focuses on the drug Tirzepatide, marketed as Mounjaro.
A groundbreaking five-year trial has launched in Greater Manchester, focusing on the effectiveness of weight loss jabs for individuals with obesity. The study, which began with the first patients enrolling at a GP visit, will provide real-world data on the health benefits of Tirzepatide, a drug marketed as Mounjaro.
This ambitious trial plans to involve up to 3,000 participants. It is a collaborative effort between US pharmaceutical giant Eli Lilly and the government, representing a £279 million investment aimed at addressing critical public health issues such as obesity.
